Class-Action Lawsuit Filed Against Remdesivir Manufacturer Over Alleged Deceptive Practices

Gilead is accused of ‘downplaying or omitting altogether the clinical dangers experienced by patients from remdesivir use.’

A vial of the drug remdesivir is visually inspected at a Gilead manufacturing site in March 2020. Gilead Sciences via AP

The company that manufactures remdesivir, used across the United States to treat COVID-19, has been hit with a class-action lawsuit over allegations it deceptively promoted the drug without disclosing possible side effects.

Two California residents, one of whom is a relative of a person who died after receiving remdesivir, lodged the suit against Gilead Sciences in Shasta County on Sept. 26.